IL325331A - Tyk2 inhibitors and compositions and methods thereof - Google Patents
Tyk2 inhibitors and compositions and methods thereofInfo
- Publication number
- IL325331A IL325331A IL325331A IL32533125A IL325331A IL 325331 A IL325331 A IL 325331A IL 325331 A IL325331 A IL 325331A IL 32533125 A IL32533125 A IL 32533125A IL 325331 A IL325331 A IL 325331A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- tyk2 inhibitors
- tyk2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2023/100508 WO2024254832A1 (en) | 2023-06-15 | 2023-06-15 | Tyk2 inhibitors and compositions and methods thereof |
| PCT/CN2024/099407 WO2024255886A1 (en) | 2023-06-15 | 2024-06-14 | Tyk2 inhibitors and compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325331A true IL325331A (en) | 2026-02-01 |
Family
ID=93851118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325331A IL325331A (en) | 2023-06-15 | 2025-12-14 | Tyk2 inhibitors and compositions and methods thereof |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2024304652A1 (en) |
| IL (1) | IL325331A (en) |
| TW (1) | TW202502764A (en) |
| WO (2) | WO2024254832A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013047813A1 (en) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivative |
| WO2013117649A1 (en) * | 2012-02-10 | 2013-08-15 | Galapagos Nv | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| JP6430390B2 (en) * | 2012-11-20 | 2018-11-28 | ジェネンテック， インコーポレイテッド | Aminopyrimidine compounds as inhibitors of EGFR mutants containing T790M |
| CN111484480B (en) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | A polycyclic derivative inhibitor, its preparation method and application |
| CN115466257A (en) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | Compound with TYK2 inhibitory activity, pharmaceutical composition containing same, and application thereof |
| TW202317561A (en) * | 2021-07-01 | 2023-05-01 | 美商羅曼德生物治療公司 | Compounds having 1h-pyrazolo[4,3-c]pyridin-6-amino as therapeutic agents |
| KR20240120732A (en) * | 2021-12-16 | 2024-08-07 | 링크 파마슈티컬스 컴퍼니 리미티드 | TYK2 inhibitors, compositions and methods thereof |
-
2023
- 2023-06-15 WO PCT/CN2023/100508 patent/WO2024254832A1/en active Pending
-
2024
- 2024-06-14 TW TW113122074A patent/TW202502764A/en unknown
- 2024-06-14 AU AU2024304652A patent/AU2024304652A1/en active Pending
- 2024-06-14 WO PCT/CN2024/099407 patent/WO2024255886A1/en active Pending
-
2025
- 2025-12-14 IL IL325331A patent/IL325331A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024254832A1 (en) | 2024-12-19 |
| AU2024304652A1 (en) | 2026-01-22 |
| WO2024255886A1 (en) | 2024-12-19 |
| TW202502764A (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4448514A4 (en) | Tyk2 inhibitors and compositions and methods thereof | |
| IL318706A (en) | Compositions and methods for inducing ferroptosis | |
| IL315862A (en) | Angiotensinogen-modulating compositions and methods of use thereof | |
| IL319049A (en) | Tyk2 inhibitors and uses thereof | |
| IL325314A (en) | Tyk2 inhibitors and compositions and methods thereof | |
| IL325331A (en) | Tyk2 inhibitors and compositions and methods thereof | |
| GB202316199D0 (en) | Compositions and methods and uses thereto | |
| GB202217944D0 (en) | Compositions and method | |
| CA3295315A1 (en) | Tyk2 inhibitors and compositions and methods thereof | |
| CA3295318A1 (en) | Tyk2 inhibitors and compositions and methods thereof | |
| GB2635318B (en) | Methods and compositions | |
| IL317852A (en) | 3-βhsd1 inhibitors and compositions and uses thereof | |
| IL321428A (en) | Compositions and methods | |
| GB202316109D0 (en) | Methods and compositions | |
| GB202311858D0 (en) | Methods and compositions | |
| GB202308901D0 (en) | Methods and compositions | |
| GB202211117D0 (en) | Compositions and methods for non-immunogenecity | |
| GB202307563D0 (en) | Methods and compositions | |
| GB202305427D0 (en) | Methods and compositions | |
| GB202304240D0 (en) | Compositions and methods | |
| IL315882A (en) | Anti-ilt4 compositions and methods | |
| GB202219851D0 (en) | Compositions and methods | |
| GB202209588D0 (en) | Methods and compositions | |
| GB202209115D0 (en) | Compositions and methods | |
| GB202206268D0 (en) | Compositions and methods |